Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Addict Rep ; 10(2): 262-271, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37266191

RESUMO

Purpose of Review: Use of "kratom" products, derived from the bioactive botanical Mitragyna speciosa have increased amidst US polydrug use epidemics. Kratom alkaloids interact with opioid, serotonergic, adrenergic, and other receptors and regular users have described experiencing a wide range of effects. Some with polydrug use histories have reported using kratom as a substitute for other drugs or to nonmedically self-manage substance use disorder (SUD) symptoms. Data describing this remain scare and come from self-report. We review this literature describing kratom use as a drug substitute, or as a nonmedical "self-treatment" for attenuating dependence or SUD symptoms. Recent Findings: Kratom products have been documented as being used as a licit and illicit opioid substitute. Use to reduce alcohol or stimulant consumption is less well documented. Although prior and current polydrug use appear common among a some kratom users, it is unclear if co-use is contemporaneous or concomitant. Temporal order of use initiation is typically undocumented. Use for energy and recreation are also increasingly reported. Summary: Data on kratom consumption come primarily from self-report with significant limitations. Until controlled human laboratory studies have been conducted, we can presently only describe what is known about human kratom use based on self-report. Such data describe real-world kratom use, leaving unaddressed human abuse liability or therapeutic potential of kratom alkaloids. Clinicians should be mindful of use motivations among people with SUD histories, sensitively assessing use. The paucity of data highlights the urgent need to increase funding and research for understanding kratom's effects in humans.

2.
ACS Chem Neurosci ; 14(2): 195-197, 2023 01 18.
Artigo em Inglês | MEDLINE | ID: mdl-36594896

RESUMO

Alkaloids from the botanical Mitragyna speciosa (commonly referred to as "kratom") interact with opioid, adrenergic, serotonergic, and other receptors to provide myriad reported effects, including analgesia, energy, improved mood, and relaxation, among others. These alkaloids are complex and unique and may serve as a blueprint for the development of novel molecules to treat various substance use disorders.


Assuntos
Mitragyna , Alcaloides de Triptamina e Secologanina , Transtornos Relacionados ao Uso de Substâncias , Humanos , Extratos Vegetais , Alcaloides de Triptamina e Secologanina/farmacologia , Analgésicos Opioides
3.
J Addict Med ; 16(2): 223-228, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34001777

RESUMO

OBJECTIVES: Kratom (Mitragyna speciosa Korth.), an indigenous medicinal plant, has been widely used as a traditional remedy in Southeast Asia. However, its combined consumption with other substances has received scarce attention. This study investigates the use of kratom among adults with a history of using heroin and methamphetamine in Malaysia. METHODS: A total of 332 patients who were mandated to undergo drug rehabilitation participated in this cross-sectional study. The study data were collected through face-to-face interviews using a semi-structured questionnaire. RESULTS: The majority were males (95%, n = 314/332) and Malays (98%, n = 325/332) with a mean age of 32.3 years (SD = 9.16). Over two thirds of the respondents used kratom to alleviate heroin withdrawal symptoms and to reduce methamphetamine intake; 59% used it as a substitute for heroin and methamphetamine. A similar proportion used kratom to reduce heroin intake (58%), while only 15% used it for its euphoric effects. Multivariate analysis showed that previous attendees of government rehabilitation programs had lower odds of using kratom as a heroin substitute. CONCLUSIONS: The potential of kratom to alleviate heroin withdrawal symptoms, and to reduce methamphetamine and heroin intake, among people who co-use heroin and methamphetamine warrants further research.


Assuntos
Metanfetamina , Mitragyna , Adulto , Estudos Transversais , Heroína , Humanos , Malásia , Masculino , Metanfetamina/efeitos adversos , Extratos Vegetais
4.
Am J Drug Alcohol Abuse ; 46(4): 485-497, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33223579

RESUMO

Background: Corrections-involved adults with a history of opioid use disorder are at elevated risk of opioid overdose following release from correctional settings. Increased opioid prescribing restrictions and monitoring during a time when heroin is becoming cheaper and ubiquitous means that adults who misused prescription opioids prior to incarceration may be reentering communities at greater risk for heroin exposure and use. Objectives: Determine risk factors of post-release heroin use among a sample of adults who participated in corrections-based drug treatment in Kentucky released between 2012 and 2017. Methods: Survey data obtained as part of an ongoing evaluation of corrections-based drug treatment were examined. Results: The final sample (N = 1,563) was majority male (80.9%). Nearly 11.0% reported past-year heroin use following their release. Depressive symptoms, polydrug use, and urban proximity were more common among participants reporting post-release heroin use. Heroin use 30 days prior to incarceration was associated with a 432.1% increase in odds of heroin use subsequent to incarceration. Post-release suicidal ideation increased odds of heroin use by 154.2%, whereas reporting satisfaction from social interactions decreased odds of use by nearly 60%. Post-release use of cocaine and diverted buprenorphine were associated with increased likelihood of heroin use during this time period, increasing odds by 469.1% and 265.9%, respectively. Residing in Central Appalachia subsequent to incarceration was associated with decreased likelihood of use. Conclusions: In this sample, post-release heroin use was associated with concerning features, such as polydrug use, lack of social satisfaction, and suicidal ideation. These features can serve as clear targets for clinical intervention.


Assuntos
Heroína , Prisões Locais/estatística & dados numéricos , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Prisioneiros/estatística & dados numéricos , Prisões/estatística & dados numéricos , Adulto , Região dos Apalaches/epidemiologia , Feminino , Humanos , Kentucky/epidemiologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Padrões de Prática Médica , Fatores de Risco , Ideação Suicida
5.
Subst Abus ; 40(2): 160-169, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30457960

RESUMO

Background: Over the past decade, availability and use of novel psychoactive substances such as synthetic cannabinoid receptor agonists (SCRA) have proliferated globally. However, the prevalence of SCRAs use remains uncertain, as does the degree to which individuals reporting SCRA use prefer SCRA to other drugs. Methods: In April 2017, a total of 500 anonymous surveys were completed by clients enrolled in a residential drug recovery program. Chi-square and t tests were used to examine significant differences between those who had ever used SCRA and those who had not. Logistic regression analysis was conducted in order to determine which other substances used within the past 12 months were significantly associated with past-12-month SCRA use. Results: About 69% (68.4%) of clients reported lifetime SCRA use. Those reporting SCRA use were predominantly younger ( x¯ = 32.5 vs. 40.7, P < .001), single (60.3% vs. 48.1%, P = .011), and white (87.1% vs. 77.7%, P = .008) and were more likely to have experienced past-12-month homelessness (6.5% vs. 3.2%, P = .004). This group had higher rates of probation/parole involvement (79.2% vs. 61.8%, P < .001) and incarceration (91.8% vs. 79.6%, P < .001). Individuals reporting SCRA use also showed extensive substance use histories and favored heroin, opioids, and amphetamines compared with SCRA. Only 5.2% of the SCRA-using group stated that SCRA was a preferred substance, and only 11.8% reported that they would try SCRA again. E-cigarettes (adjusted odds ratio [AOR] = 1.88), traditional cannabis (AOR = 3.87), amphetamines (AOR = 2.20), and synthetic cathinones (AOR = 3.51) were significantly associated with past-12-month SCRA use. Motivations for use included circumnavigating drug screens and peer influence. Approximately half of those who tried SCRA reported adverse effects associated with use. Conclusions: Prevalence of SCRA use among individuals with a history of substance misuse and criminal justice system involvement is high; however, SCRA are not indicated as a preferred drug.


Assuntos
Agonistas de Receptores de Canabinoides , Comportamento do Consumidor , Direito Penal/estatística & dados numéricos , Pessoas Mal Alojadas/estatística & dados numéricos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Medicamentos Sintéticos , Adolescente , Adulto , Distribuição por Idade , Alcaloides , Transtornos Relacionados ao Uso de Anfetaminas/epidemiologia , Feminino , Dependência de Heroína/epidemiologia , Humanos , Kentucky/epidemiologia , Modelos Logísticos , Masculino , Uso da Maconha/epidemiologia , Estado Civil/estatística & dados numéricos , Pessoa de Meia-Idade , Motivação , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Prevalência , Vaping/epidemiologia , Adulto Jovem
6.
Drug Alcohol Depend ; 180: 340-348, 2017 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-28950240

RESUMO

BACKGROUND: Kratom use in the West has increased recently, yet the prevalence and motives for use among individuals with a history of substance use disorder (SUD) have not been fully examined. Kratom has been documented as a means of treating chronic pain, mitigating drug dependence, and easing withdrawal symptoms, yet it is unclear if substance users are utilizing kratom as a self-medication. Abuse liability, side effects, and overall appeal of kratom remain uncertain. METHODS: In April 2017, an anonymous survey regarding kratom use and motivations was completed by clients enrolled in a 12-Step-oriented residential program. 500 respondents with a self-reported history of SUD completed the survey. RESULTS: 20.8% of respondents endorsed lifetime kratom use and 10.2% reported past-12-month use. Kratom-users were younger (=32.1 vs. 35.9, p<0.001) and were more versatile substance users. A majority (68.9%) of kratom-users reported having used the drug as a means of reducing or abstaining from non-prescription opioids (NPO) and/or heroin, and 64.1% reported using kratom as a substitute for NPO/heroin. 18.4% of kratom-users reported using the drug due to a disability or chronic pain. One-third of kratom-users stated that kratom was a helpful substance and that they would try it again. However, kratom was not preferred and was indicated as having less appeal than NPO, heroin, amphetamines, and Suboxone. CONCLUSIONS: Among substance users, kratom use may be initiated for a variety of reasons, including as a novel form of harm-reduction or drug substitution, particularly in the context of dependence and withdrawal from other substances.


Assuntos
Analgésicos Opioides/uso terapêutico , Combinação Buprenorfina e Naloxona/uso terapêutico , Dor Crônica/tratamento farmacológico , Heroína/uso terapêutico , Tratamento Domiciliar , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Anfetaminas , Humanos , Motivação , Prevalência , Automedicação , Autorrelato , Inquéritos e Questionários
7.
J Psychoactive Drugs ; 49(5): 436-445, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28813207

RESUMO

Use of novel psychoactive substances (NPS) such as synthetic cannabinoids (e.g., "Spice," "Serenity") and cathinones (e.g., "bath salts") has proliferated in recent years; however, there is a gap in research examining prevalence among offender samples. This study examined demographics, drug use, mental health characteristics, and criminal histories of NPS users compared to non-NPS users within an offender sample entering drug treatment. Using logistic regression analysis, combined 2013-2015 assessment data were examined (N = 8,791). NPS users offended more often (x̄ = 10.3), were more likely to have experienced homelessness (12.2%), and to have lived in a metro area (59.0%). NPS users reported significantly more past-year drug use, including substances not readily detected by standard urine analysis (e.g., hallucinogens, alcohol, and inhalants). Individuals with higher anxiety symptom counts (OR = 1.07; p < .001) and those who reported drinking to intoxication (OR = 1.30; p < .001) had an increased likelihood of NPS use. Older individuals (OR = 0.95; p < .001) and those who began using drugs at an older age (OR = 0.95; p < .001) were less likely to report NPS use. NPS use may be a marker of more severe using patterns in an offender sample. Future investigation should focus on NPS use as a possible method for bypassing drug testing measures.


Assuntos
Alcaloides/efeitos adversos , Canabinoides/efeitos adversos , Usuários de Drogas/psicologia , Prisioneiros/psicologia , Psicotrópicos/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/psicologia , Adulto , Fatores Etários , Intoxicação Alcoólica/epidemiologia , Intoxicação Alcoólica/psicologia , Ansiedade/epidemiologia , Ansiedade/psicologia , Comportamento Aditivo , Canabinoides/síntese química , Distribuição de Qui-Quadrado , Feminino , Pessoas Mal Alojadas/psicologia , Humanos , Kentucky , Modelos Logísticos , Masculino , Análise Multivariada , Razão de Chances , Prevalência , Psicotrópicos/síntese química , Fatores de Risco , Detecção do Abuso de Substâncias , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/reabilitação , Fatores de Tempo , População Urbana , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...